10x Genomics, Inc. (TXG) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TXG Revenue Growth
Revenue Breakdown (FY 2025)
TXG's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
TXG Revenue Analysis (2017–2025)
As of May 8, 2026, 10x Genomics, Inc. (TXG) generated trailing twelve-month (TTM) revenue of $642.8 million, reflecting modest growth of +0.6% year-over-year. The most recent quarter (Q4 2025) recorded $166.0 million in revenue, up 11.4% sequentially.
Looking at the longer-term picture, TXG's 5-year compound annual growth rate (CAGR) stands at +16.6%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $642.8 million in 2025, representing a new all-time high.
Revenue diversification analysis shows TXG's business is primarily driven by Product And Service Revenue (48%), Consumables (41%), and Instruments (5%).
When compared to Healthcare sector peers including PACB (+3.9% YoY), ILMN (+1.2% YoY), and BRKR (+0.4% YoY), TXG has underperformed the peer group in terms of revenue growth. Compare TXG vs PACB →
TXG Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TXGCurrent | $643M | +0.6% | +16.6% | -17.2% | |
 PACB | $160M | +3.9% | +15.2% | -348.5% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% | |
 BRKR | $3.4B | +0.4% | +11.6% | 6.9% | |
 FLGT | $323M | +13.8% | -5.2% | -28.2% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% |
TXG Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $642.8M | +5.2% | $443.9M | 69.1% | $-110,885,000 | -17.2% |
| 2024 | $610.8M | -1.3% | $414.5M | 67.9% | $-194,559,000 | -31.9% |
| 2023 | $618.7M | +19.8% | $409.3M | 66.2% | $-265,329,000 | -42.9% |
| 2022 | $516.4M | +5.3% | $396.0M | 76.7% | $-167,944,000 | -32.5% |
| 2021 | $490.5M | +64.1% | $416.4M | 84.9% | $-52,913,000 | -10.8% |
| 2020 | $298.8M | +21.5% | $240.4M | 80.4% | $-85,324,000 | -28.6% |
| 2019 | $245.9M | +68.1% | $184.9M | 75.2% | $-29,071,000 | -11.8% |
| 2018 | $146.3M | +105.8% | $117.7M | 80.4% | $-110,764,000 | -75.7% |
| 2017 | $71.1M | - | $60.5M | 85.1% | $-18,375,000 | -25.8% |
See TXG's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TXG Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TXG vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTXG — Frequently Asked Questions
Quick answers to the most common questions about buying TXG stock.
Is TXG's revenue growth accelerating or slowing?
TXG revenue growth slowed to +0.6%, below the 5-year CAGR of +16.6%. TTM revenue is $643M. The deceleration marks a shift from historical growth rates.
What is TXG's long-term revenue growth rate?
10x Genomics, Inc.'s 5-year revenue CAGR of +16.6% reflects the variable expansion pattern. Current YoY growth of +0.6% is near this long-term average.
How is TXG's revenue distributed by segment?
TXG reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.